Gan & Lee Pharmaceuticals. (SHA:603087)
China · Delayed Price · Currency is CNY 66.96
-1.35 (-1.98%)
Oct 28, 2026, 10:45 AM CST
SHA:603087 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 39,863 | 40,515 | 26,332 | 31,066 | 18,429 | 39,499 | |
Market Cap Growth | -2.70% | 53.87% | -15.24% | 68.57% | -53.34% | -46.80% |
Enterprise Value | 35,912 | 37,352 | 21,268 | 26,918 | 13,463 | 34,935 |
Last Close Price | 68.31 | 66.79 | 42.53 | 50.02 | 30.95 | 66.39 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 33.48 | 35.43 | 42.84 | 91.35 | - | 27.19 |
Forward PE | 25.77 | 33.53 | 28.27 | 52.09 | 11.40 | 25.81 |
PS Ratio | 9.30 | 10.00 | 8.65 | 11.91 | 10.76 | 10.94 |
PB Ratio | 3.40 | 3.48 | 2.38 | 2.89 | 1.92 | 3.89 |
P/TBV Ratio | 3.58 | 3.57 | 2.44 | 2.97 | 1.98 | 4.00 |
P/FCF Ratio | - | - | 272.84 | - | - | 102.30 |
P/OCF Ratio | 42.11 | 51.66 | 49.01 | 283.83 | 62.12 | 36.64 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.39 | 9.22 | 6.98 | 10.32 | 7.86 | 9.67 |
EV/EBITDA Ratio | 28.83 | 35.34 | 38.63 | 67.16 | - | 22.24 |
EV/EBIT Ratio | 39.15 | 49.16 | 72.20 | 149.52 | - | 25.13 |
EV/FCF Ratio | - | - | 220.38 | - | - | 90.48 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0 | 0 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.18 | 0.00 | 0.01 | 0.02 | - | 0.01 |
Debt / FCF Ratio | - | - | 0.05 | - | - | 0.05 |
Net Debt / Equity Ratio | -0.34 | -0.33 | -0.22 | -0.45 | -0.49 | -0.51 |
Net Debt / EBITDA Ratio | -3.18 | -3.60 | -4.36 | -12.09 | 9.82 | -3.30 |
Net Debt / FCF Ratio | 11.03 | 26.87 | -24.86 | 10.92 | 6.86 | -13.44 |
Asset Turnover | 0.34 | 0.33 | 0.26 | 0.23 | 0.16 | 0.36 |
Inventory Turnover | 0.96 | 0.96 | 0.81 | 0.96 | 0.68 | 0.70 |
Quick Ratio | 4.18 | 5.41 | 3.33 | 6.77 | 6.05 | 12.65 |
Current Ratio | 5.39 | 6.72 | 4.73 | 7.99 | 6.97 | 14.15 |
Return on Equity (ROE) | 10.17% | 10.08% | 5.64% | 3.35% | -4.45% | 15.21% |
Return on Assets (ROA) | 4.54% | 3.85% | 1.55% | 1.01% | -3.94% | 8.54% |
Return on Invested Capital (ROIC) | 11.03% | 8.58% | 3.95% | 3.34% | -13.72% | 25.45% |
Return on Capital Employed (ROCE) | 7.50% | 6.40% | 2.60% | 1.60% | -6.90% | 13.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.99% | 2.82% | 2.33% | 1.09% | -2.38% | 3.68% |
FCF Yield | -0.90% | -0.35% | 0.37% | -1.43% | -3.73% | 0.98% |
Dividend Yield | 1.49% | 1.46% | 3.41% | 0.38% | - | 0.43% |
Payout Ratio | 50.50% | 52.25% | 68.42% | - | - | 15.46% |
Buyback Yield / Dilution | 0.22% | -0.26% | -4.28% | -0.58% | -0.46% | -5.28% |
Total Shareholder Return | 1.68% | 1.20% | -0.86% | -0.21% | -0.46% | -4.86% |